Affinity Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Affinity Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18,250	Closed	-$2.05M	–	151
2018 Q2	$2.05M	Buy	18,250 +40	+0.2%	+$4.32K	0.29%	81
2018 Q1	$1.94M	Hold	18,210	–	–	0.23%	83
2017 Q4	$1.99M	Hold	18,210	–	–	0.23%	87
2017 Q3	$1.97M	Sell	18,210 -2,910	-14%	-$299K	0.23%	79
2017 Q2	$2.14M	Sell	21,120 -15,792	-43%	-$1.45M	0.25%	85
2017 Q1	$3.32M	Sell	36,912 -240	-0.6%	-$20.4K	0.3%	88
2016 Q4	$2.83M	Sell	37,152 -15,033	-29%	-$1.14M	0.27%	94
2016 Q3	$4.35M	Sell	52,185 -19,493	-27%	-$1.63M	0.37%	82
2016 Q2	$5.91M	Buy	71,678 +30,066	+72%	+$2.48M	0.44%	79
2016 Q1	$3.16M	Buy	+41,612	New	+$3.08M	0.28%	83

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Affinity Investment Advisors's CRL Position: Q3 2018 in Review

Affinity Investment Advisors sold out of Charles River Laboratories (CRL) in Q3 2018, closing a stake of 18,250 shares — an estimated $2.05M sold.

Affinity Investment Advisors first reported a position in CRL in Q1 2016 and held it in 10 quarters. The position peaked at $5.91M in Q2 2016. 366 funds tracked by Wall St. Rank hold CRL as of Q3 2018.

Affinity Investment Advisors reported no remaining Charles River Laboratories position as of Q3 2018 after selling out during the quarter.
Affinity Investment Advisors sold 18,250 Charles River Laboratories shares in Q3 2018, an estimated $2.05M.
Affinity Investment Advisors first reported a position in Charles River Laboratories in Q1 2016 and held it in 10 quarters.
Affinity Investment Advisors's Charles River Laboratories position peaked at $5.91M in Q2 2016.
366 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2018.

Based on Affinity Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.